For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Pinealon (Glu-Asp-Arg, EDR) is a synthetic tripeptide isolated from the polypeptide neuroprotective drug Cortexin and developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is the most clinically supported Khavinson bioregulator other than Pancragen: oral administration in 72 patients with traumatic brain injury consequences (0.2 mg twice daily, 20 to 30 days, with a 37-patient control group) produced improvements in memory, headache reduction, emotional stability, and EEG alpha-index changes. Additional published rodent data include prenatal neuroprotection, hypoxia tolerance, cognitive improvement across aging models, and dendritic spine preservation in Alzheimer's and Huntington's disease cell models. The 2021 MDPI Molecules open-access review provides the most comprehensive mechanistic characterization to date. No randomized controlled trial has been published.
Pinealon is a research compound with no FDA or EMA approval. It does have published indexed human data: a study in 72 patients with traumatic brain injury consequences and cerebrasthenia (ages 30 to 74 years) who received oral Pinealon at 0.2 mg twice daily for 20 to 30 days in addition to standard therapy, with a 37-patient control group receiving standard therapy only. The Khavinson/Linkova/Umnov 2013 Advances in Gerontology paper cites this as showing improvements in memory, reduced headache duration and intensity, emotional balance, enhanced performance, and increased EEG alpha-index. A second Russian clinical observation involving occupational cognitive support in truck drivers was published by Bashkireva and Artamonova (2012, Advances in Gerontology). Neither study is a randomized, blinded, placebo-controlled trial. Both originate from the St. Petersburg Institute ecosystem.
An important naming clarification that most vendor content ignores: Pinealon is not derived from the pineal gland. It was isolated from Cortexin, a polypeptide complex derived from bovine brain cortex and brainstem tissue. The name "Pinealon" does not reflect the compound's tissue of origin. Vendor content claiming Pinealon "targets the pineal gland" or "restores melatonin production" as a primary mechanism is extrapolating far beyond the published evidence. The proposed melatonin-restoration mechanism has no direct experimental support and is based on indirect reasoning from the compound's circadian behavior effects in animal models.
The entire primary research base for Pinealon originates from the St. Petersburg Institute of Bioregulation and Gerontology, with Professor Khavinson as senior author on essentially all key publications. The 2021 MDPI Molecules open-access paper (Khavinson, Linkova, Kozhevnikova, Trofimova) provides international publication with external peer review but Khavinson remains the senior author. The 2017 Huntington's disease paper lists international co-authors including a Karolinska Hospital affiliate, providing some institutional breadth.
Pinealon (EDR) is a synthetic tripeptide with the sequence Glu-Asp-Arg, developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike the tetrapeptide Khavinson bioregulators (Epithalon, Cardiogen, Vesugen, Pancragen, Cortagen, Livagen), Pinealon is a tripeptide, placing it in the same minimal structural category as Thymogen (Glu-Trp) and making it one of the smallest neuroprotective peptides in the bioregulator family.
Pinealon was isolated through directed analysis of Cortexin, a polypeptide neuroprotective drug derived from bovine and porcine brain cortex tissue that has been used clinically in Russia and Eastern Europe for decades in neurological conditions including stroke, traumatic brain injury, and epilepsy. Khavinson's team identified EDR as one of the shortest active peptide sequences within Cortexin that replicates the parent compound's neuroprotective effects. This origin from a clinically used polypeptide preparation distinguishes Pinealon from family members derived purely from tissue amino acid analysis, and gives it a claim to representing an active fraction of an established drug rather than purely a synthesized candidate.
The name "Pinealon" is misleading and deserves explicit correction. The compound is not derived from pineal gland tissue. Epithalon (AEDG) is the Khavinson bioregulator actually designed for the pineal gland. Pinealon's name was assigned to reflect proposed effects on brain and circadian function rather than tissue origin. Substantial vendor content incorrectly states that Pinealon targets or is derived from the pineal gland. This conflation creates confusion in the bioregulator market and can mislead consumers about the compound's mechanism and intended applications.
Pinealon has been investigated across a broader range of experimental neurological contexts than most Khavinson bioregulators: traumatic brain injury, prenatal neuroprotection, hypoxia tolerance, Alzheimer's disease in vitro models, Huntington's disease in vitro models, cognitive aging in rats and primates, circadian disruption, and occupational neurotoxicology. This breadth reflects the fact that Pinealon's proposed mechanism, epigenetic gene expression modulation in neural tissue, is relevant across many neurological pathologies rather than one specific organ system.
Pinealon's mechanism involves two distinct pathways: direct nuclear access and epigenetic gene regulation, and antioxidant/anti-apoptotic signaling in neuronal cells.
The nuclear access mechanism follows the Khavinson bioregulator framework. Fedoreyeva et al. (2011, Biochemistry/Biokhimiia) demonstrated using fluorescein-labeled peptide studies in HeLa cells that short peptides including EDR penetrate both cellular and nuclear membranes and interact with double-stranded DNA and deoxyribooligonucleotides. The 2017 Huntington's disease paper by Khavinson, Linkova et al. (Journal of Neurology and Neuroscience) used molecular docking to show that EDR binds specific oligo-dCG sequences in the DNA minor groove. The 2021 MDPI Molecules review paper identified EDR binding sites in the promoter regions of CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG, and GDX1. These genes collectively represent apoptosis regulators (CASP3, p53), neuronal differentiation markers (NES, GAP43), Alzheimer's pathogenesis genes (APOE), antioxidant enzymes (SOD2), and inflammatory regulators (PPARA, PPARG). The breadth of this gene set is consistent with a broad epigenetic regulator that restores expression programs silenced in aging or diseased neural tissue.
The 2021 MDPI Molecules paper (Khavinson, Linkova, Kozhevnikova, Trofimova) provides the most detailed mechanistic analysis, characterizing Pinealon's effects across five distinct features of Alzheimer's disease pathology: it normalizes serotonin synthesis (tryptophan hydroxylase expression), restores antioxidant balance via MAPK-ERK signaling and SOD2/GPX1 upregulation, suppresses neuronal apoptosis (caspase-3 reduction, p53 reduction), reduces neuroinflammation (PPARA and PPARG normalization), and preserves dendritic spine density. Each of these is a recognized pathological feature of Alzheimer's disease, making the claim of broad AD-relevant neuroprotection mechanistically coherent.
In the antioxidant/anti-apoptotic pathway, the 2011 Rejuvenation Research paper (Khavinson, Ribakova, Kulebiakin, Vladychenskaya, Kozina, Arutjunyan, Boldyrev) examined Pinealon in cerebellar granule cell culture under oxidative stress conditions. Pinealon increased the lag phase of MAPK/ERK kinase activation from 2.5 minutes to 20 minutes when cells faced oxidative challenge, suppressed ROS accumulation, and increased cell viability. The delayed ERK activation is neuroprotective because rapid, excessive ERK activation under oxidative stress drives apoptosis; delaying the response gives cells time to engage protective mechanisms.
The 2012 prenatal hyperhomocysteinemia rat study (Arutjunyan, Kozina, Stvolinskiy, Bulygina, Mashkina, Khavinson, International Journal of Clinical and Experimental Medicine) provided the most extensive in vivo mechanistic characterization. Maternal Pinealon administration prevented ROS accumulation and necrotic cell formation in offspring brains, preserved behavioral and motor coordination endpoints, and normalized hippocampal neuron morphology. Hyperhomocysteinemia is a model of oxidative and excitotoxic neural stress; the protection demonstrates Pinealon's functional significance in a whole-animal developmental model.
One mechanism frequently cited in vendor content, melatonin restoration via pineal gland targeting, lacks direct experimental support in the indexed literature. The circadian and sleep benefits observed in some animal models and the truck driver study are attributed to normalized brain gene expression and neurotransmitter synthesis rather than direct melatonin pathway activation. The naming "Pinealon" creates a natural inference of pineal gland targeting that is not substantiated by the evidence base.
In the 72-patient TBI clinical observation (ages 30 to 74), oral Pinealon at 0.2 mg twice daily for 20 to 30 days added to standard therapy produced: improvements in memory and attention; reduced duration and intensity of headaches; improved emotional balance and stability; enhanced work performance; and a significant increase in the EEG alpha-index when measuring bioelectric activity of the brain.
In the control group of 37 TBI patients receiving standard therapy without Pinealon, these improvements were not observed. Patients with long-term TBI consequences showed a decreased number of errors in the correction test. The authors interpreted the alpha-index increase as evidence that Pinealon stimulated neuroplasticity and integrative function of brain neurons after traumatic injury.
A separate finding cited in the same review context reports that 59.4% of patients with cranial trauma showed improved symptoms, 31.9% showed satisfactory results, and 8.7% experienced no positive effect. These outcomes are not from the same 72-patient series but from a broader observational context.
The most important limitation of the 72-patient study is that it is not a randomized, blinded, or placebo-controlled trial. The control group received standard therapy but was not matched or randomized. The study was conducted within the St. Petersburg Institute ecosystem. The primary publication is in Advances in Gerontology, a Russian-language journal that also publishes English translations. These limitations are significant but the n=72 with a defined 37-patient comparator group represents more human clinical structure than most Khavinson bioregulators have.
The TBI clinical observation is the most substantive human data in the Pinealon profile. A 72-patient series with a 37-patient comparator group, objective EEG endpoints alongside subjective outcomes, and a defined oral dose (0.2 mg twice daily) is a meaningful clinical signal. The absence of randomization, blinding, and placebo control, combined with single-institution origin, limits the confidence level. It is Tier 3, Low: a structured observational study but not an RCT.
The 2021 Molecules review by Khavinson et al. systematically mapped Pinealon's effects against five pathological features of Alzheimer's disease: (1) serotonin synthesis impairment: EDR normalized tryptophan hydroxylase expression; (2) antioxidant system imbalance: EDR suppressed MAPK-ERK overactivation, upregulated SOD2 and GPX1; (3) neuronal apoptosis: EDR reduced caspase-3 activity and p53 expression; (4) neuroinflammation: EDR normalized PPARA and PPARG transcription factor expression; (5) dendritic spine loss: EDR prevented spine elimination in hippocampal cultures.
The 2017 Kraskovskaya et al. BEMBM study showed that EDR increased the number of mushroom-shaped dendritic spines to 71% of control values in primary hippocampal cultures treated with amyloid beta-42. Mushroom spines are the morphologically stable form associated with long-term memory; their selective preservation by Pinealon in an amyloid synaptotoxicity model is the most specific neuroprotective finding in the AD literature for this compound.
The 2021 Pharmaceuticals paper (5xFAD mouse model) showed EDR prevented dendritic spine loss in the in vitro amyloid synaptotoxicity companion model, and molecular docking identified EDR binding sites in the promoters of CASP3, NES, GAP43, APOE, SOD2, PPARA, PPARG, and GDX1, connecting the epigenetic mechanism to the specific AD-relevant gene targets.
These findings are from cell culture models and transgenic mouse models. The 5xFAD model uses five familial AD mutations and represents aggressive, non-typical disease. Mushroom spine preservation in cultured hippocampal cells does not establish clinical efficacy in human Alzheimer's disease.
The Alzheimer's disease mechanistic portfolio is the most systematically developed body of evidence in the Pinealon literature, spanning cell culture, transgenic mouse models, and molecular docking, all published in indexed international journals. The specificity of mushroom spine preservation in the 71% recovery finding is a meaningful in vitro result. The limitation is that these are entirely model systems, and the compound has not been tested in any human Alzheimer's disease study. The multi-pathway mechanistic coherence is impressive but coherence is not efficacy.
The 2012 Arutjunyan et al. prenatal study (PMC open-access) administered Pinealon maternally in a rat hyperhomocysteinemia model. Homocysteine is both an oxidative stress driver and an NMDA receptor overactivator in developing neurons. Offspring from Pinealon-treated mothers showed significantly reduced ROS accumulation in brain tissue, reduced necrotic cell formation, preserved behavioral and motor coordination, and normalized hippocampal neuron morphology compared to hyperhomocysteinemia controls.
The 2011 Rejuvenation Research cell viability study found that Pinealon in cerebellar granule cells under oxidative stress delayed MAPK/ERK kinase activation from 2.5 minutes to 20 minutes. Rapid MAPK/ERK activation under oxidative stress drives pro-apoptotic signaling; delaying this response by 8-fold allows cells more time to engage survival mechanisms. Pinealon also suppressed ROS accumulation directly and increased cell viability in a dose-dependent manner.
The 2008 Kozina antihypoxia study in rodent models found that short peptides including Pinealon improved survival and behavioral outcomes under conditions of hypoxic challenge, providing a whole-animal correlate for the cellular antioxidant findings.
The prenatal study is notable because maternal administration protecting offspring demonstrates systemic access and a time-locked biological effect: changes in the developing brain from a compound administered to the mother require that the compound or a signal it triggers must cross the placenta or modify maternal biology in ways that protect fetal neural tissue.
The prenatal hyperhomocysteinemia study is one of the more mechanistically complete Pinealon in vivo studies, with multiple endpoint types (biochemical, behavioral, morphological) in a whole-animal model with genuine translational relevance (hyperhomocysteinemia is a recognized human neurological risk factor). The cell viability study provides the mechanistic explanation for the in vivo findings. These are rodent studies; no prenatal or neonatal human studies exist.
The 2014 Mendzheritsky et al. study tested Pinealon alongside Cortexin (the parent polypeptide from which Pinealon was isolated) in aged rats using the Morris water maze navigation task. Pinealon improved navigation learning performance in aged rats, with reduced caspase-3 activity in hippocampal and cortical structures consistent with reduced apoptosis. The 2021 Pharmaceuticals paper (5xFAD Alzheimer's model) cited that Pinealon outperformed Cortexin in dendritic spine preservation and apoptosis reduction in cell culture, establishing that the purified tripeptide can exceed the parent compound's effects in defined model systems.
The 2019 rhesus macaque study examined Pinealon in aged female macaques on spatial orientation tasks. A 1.5-fold increase in learning speed was reported, alongside improvements in attention and memory parameters. This primate study is the closest Pinealon data to human relevance outside the TBI clinical observation, given rhesus monkey cognitive aging physiology closely parallels human aging.
The truck driver occupational study (Bashkireva and Artamonova 2012, Advances in Gerontology) examined Pinealon in professional truck drivers experiencing neurotic disorders associated with occupational stress and poor sleep. Improvements in psychoemotional state, stress markers, and sleep quality were reported. This is the most directly applicable human observational finding in a non-TBI population, but it is uncontrolled and in Russian-language literature.
The cognitive aging data span rodent Morris water maze performance through primate spatial learning to human truck driver occupational health, establishing a consistent directional signal for cognitive support across species and conditions. The primate spatial learning 1.5-fold improvement is a quantified, specific finding in a species relevant to human cognition. All findings remain observational or preclinical; no randomized cognitive aging trial has been published.
The 2017 Khavinson et al. Huntington's disease paper (Journal of Neurology and Neuroscience) demonstrated that EDR restored the morphology of dendritic spines in striatal neurons in an HD mouse model. The molecular docking analysis showed that EDR binds specifically to oligo-dCG sequences in the DNA minor groove, providing a structural explanation for the gene-level effects in neurons. The HD model uses mutant huntingtin protein expression, which produces spine loss through cytoskeletal disruption; the reversal of this morphological change by EDR indicates neuroprotective activity at a synaptic level.
The Drosophila HD model is also cited in the secondary literature, where EDR improved motor performance (larval crawling and climbing activity) at the highest tested concentration of 3 micrograms. This cross-species finding in a non-mammalian model adds breadth to the neuroprotective signal.
The 2021 Pharmaceuticals paper extended the HD findings by characterizing that EDR prevents dendritic spine loss in the 5xFAD Alzheimer's mouse model as well, establishing that the spine-preservation mechanism is not disease-specific but reflects a general mechanism of protecting synaptic architecture under neurodegenerative stress.
EDR's effect on medium spiny neurons in the striatum (the cell population most affected in Huntington's disease) is mechanistically specific to HD biology, making this one of the more disease-targeted preclinical findings in the Pinealon literature.
The Huntington's disease striatal spine restoration finding is a specific and disease-relevant in vivo result. The multi-level evidence (mouse model striatum, Drosophila motor performance, molecular docking CG sequence binding) provides mechanistic coherence. Huntington's disease has no effective disease-modifying treatment, making any genuine preclinical signal worth noting. All data are preclinical; no human HD study has been published.
Khavinson bioregulator for pineal gland support.
The 2013 Umnov et al. TBI clinical observation is the basis for humanDataAvailable being True, establishing that 0.2 mg oral twice daily for 20 to 30 days was tolerated and produced measurable outcomes in 72 patients. However, this is a single uncontrolled observational study; 0.2 mg is extremely low by current commercial protocol standards (which suggest 5 to 20 mg). The 25 to 100-fold dose discrepancy between the published human data and commercial protocols has no published pharmacokinetic or dose-finding justification. Doses shown (200 to 1000 mcg) reflect a middle range between the documented human oral dose and low-end commercial injectable protocols.
Within the Khavinson bioregulator family, Pinealon has the most developed neuroprotection evidence portfolio and the second-most clinical human data after Pancragen. Cortexin, the parent polypeptide from which Pinealon was isolated, has genuine clinical data in stroke and TBI patients in Russia and Eastern Europe, and has been the subject of a published RCT in some contexts. Pinealon is intended as the purified active fraction of Cortexin; however, whether the isolated tripeptide replicates the full clinical utility of the complex mixture it came from is not established. Among neuroprotective compounds reviewed in this series, Cerebrolysin has the strongest clinical evidence base (Phase 2 and Phase 3 data in vascular dementia and Alzheimer's disease, 35+ countries approved), while Semax has Russian regulatory approval and a narrower but defined clinical indication in ischemic stroke. Pinealon sits between these established compounds and the purely preclinical bioregulators, with more human signal than the preclinical-only family members but far less controlled evidence than either Cerebrolysin or Semax.
Pinealon is the Khavinson bioregulator with the most human-relevant safety context: 72 patients with traumatic brain injury consequences received oral Pinealon for 20 to 30 days with no reported adverse effects, and the therapeutic benefits were described as occurring without complications. A second human observational study in truck drivers also reported no adverse effects. These represent minimal human safety data but are more than most family members have.
In animal studies, including prenatal administration to pregnant rats and chronic administration to aged rodents across multiple studies, no organ toxicity, behavioral abnormality, or developmental defect has been reported in any published Pinealon study. The compound is derived from normal amino acids present in human physiology.
Vendor content mentions theorized adverse effects including headache, vivid dreams, mild insomnia if taken late in the day, and mild anxiety or dizziness. These are extrapolations from the CNS-active peptide class rather than Pinealon-specific reported findings. The concern about lowering seizure threshold in epilepsy patients is similarly a theoretical precaution based on CNS activity class, not a documented finding.
No human pharmacokinetic study has been published. No drug interaction data exist. The oral route used in the TBI clinical observation (0.2 mg twice daily) differs substantially from injectable commercial protocols suggesting 5 to 20 mg, a 25 to 100-fold dose difference with no published justification for the higher doses.
A note on the parent compound Cortexin: Cortexin has been in Russian clinical use for stroke, TBI, and epilepsy for decades and has a published safety profile in thousands of patients. Pinealon was identified as an active fraction of Cortexin; the safety data for Cortexin provide indirect support for Pinealon's tolerability but cannot substitute for Pinealon-specific safety data at the doses being commercially recommended.
Pinealon occupies a distinctive position in the Khavinson bioregulator family: it is the most extensively tested in terms of preclinical scope, spanning Alzheimer's and Huntington's disease models, prenatal neuroprotection, cognitive aging in primates, and hypoxia tolerance, while also having two human observational studies (TBI patients, truck drivers) that provide clinical directional signals beyond pure preclinical work.
The 72-patient TBI observational study, with its 37-patient comparator group and objective EEG endpoint, is the most structured human dataset for any Khavinson tripeptide or the closest structural neighbors. The rhesus macaque 1.5-fold spatial learning improvement is the most quantified primate cognitive finding in the bioregulator series. The 71% mushroom spine recovery in hippocampal amyloid cultures and the multi-pathway AD pathogenesis analysis in the 2021 MDPI Molecules paper represent the most coherently mechanistic preclinical portfolio among the Khavinson compounds reviewed.
What Pinealon has not achieved in 15-plus years of research is a single randomized controlled trial. The TBI observational study, while useful, was published in 2013 and has not been followed up with an RCT in a decade. The cognitive aging data in primates (2019) has not led to a human aging trial. The AD in vitro findings have not moved to animal efficacy or human pilot studies. This pattern of promising preclinical and observational findings without clinical trial progression is the defining limitation of the entire Khavinson bioregulator program.
The naming misnomer deserves explicit reiteration: Pinealon is not a pineal gland compound. It was isolated from Cortexin, a brain cortex polypeptide preparation. Vendors and even some review papers claiming Pinealon "supports the pineal gland" or "restores melatonin production" are making claims not supported by the primary literature. The circadian and sleep effects observed in animal and occupational models likely reflect normalized brain gene expression relevant to circadian signaling rather than direct pineal gland activation.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use